The Therapeutic Potential of CRTH2/DP2 Beyond Allergy and Asthma

    August 2017 in “ Prostaglandins & Other Lipid Mediators ”
    Katharina Jandl, Akos Heinemann
    Image of study
    TLDR CRTH2 antagonists might be useful for treating many conditions because they play a role in immune and inflammation responses.
    The document from 2017 reviews the role of the CRTH2/DP2 receptor, which is activated by prostaglandin D2 (PGD2), in various diseases beyond allergy and asthma, including the nervous system, kidney, intestine, lung, hair and skin, bone and cartilage, and cancer. It suggests that CRTH2 antagonists could be a potential therapeutic target for a wide range of conditions due to their involvement in immune and inflammatory responses. The review discusses the effects of CRTH2 antagonists in clinical trials for asthma, allergic rhinitis, and eosinophilic esophagitis, and their potential in treating inflammatory bowel diseases, cognitive dysfunction, autoimmune diseases, lung and kidney fibrosis, and androgenic alopecia. The document indicates that while the role of CRTH2 in cancer is still unclear, its broad presence in various cell types and tissues makes it a promising target for future therapeutic interventions.
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results

    Related Community Posts Join

    4 / 4 results

      community Fevipiprant 2019!

       17 upvotes 8 years ago
      The conversation discusses Fevipiprant, an asthma drug that may block CRTH2 and potentially stop male pattern baldness (MPB) without inhibiting DHT. It also mentions the use of finasteride and dutasteride for hair loss.

      community SETIPIPRANT PGE2 GROUP BUY AND PIONEERING HAIR GROWTH

       7 upvotes 8 years ago
      The conversation is about a user seeking help with hair regrowth treatments, specifically mentioning Setipiprant, Minoxidil, Finasteride, and RU58841. The user is trying to contact forum members for guidance on making and using these treatments.

      community The New, Improved CB-03-01/Setipiprant Group Buy

       27 upvotes 8 years ago
      The group buy for CB-03-01, a topical anti-androgen for hair loss, was postponed and refunded due to issues with the product's form and solubility. The product, also known as Breezula, is an alternative to finasteride with fewer side effects, but its official release is delayed until 2021.

    Related Research

    1 / 1 results